Free Helpline
We are here to assist you.
Health Advisor
+91-8877772277Available 7 days a week
10:00 AM – 6:00 PM to support you with urgent concerns and guide you toward the right care.
We are here to assist you.
Health Advisor
+91-8877772277Available 7 days a week
10:00 AM – 6:00 PM to support you with urgent concerns and guide you toward the right care.
Explore how Cabenuva, the long-acting HIV injectable, impacts reproductive health, including pregnancy, fertility, and contraception. Learn essential considerations for family planning and sexual well-being while on this innovative medication.
Living with HIV requires careful management, and advancements in treatment have significantly improved the quality of life for many. Cabenuva, an injectable long-acting regimen for HIV-1 infection, represents a major step forward, offering a less frequent dosing schedule compared to daily oral pills. While its convenience is a significant benefit, understanding how Cabenuva interacts with various aspects of health, particularly reproductive health, is crucial for individuals planning families or managing their sexual health.
This comprehensive guide delves into Cabenuva's implications for pregnancy, fertility, contraception, and overall reproductive well-being. We'll explore the available data, expert recommendations, and essential considerations to help you make informed decisions in consultation with your healthcare provider.
Cabenuva is a complete regimen for the treatment of HIV-1 infection in adults and adolescents who are virologically suppressed (HIV-1 RNA less than 50 copies/mL) on a stable antiretroviral regimen, with no history of treatment failure and no known or suspected resistance to either cabotegravir or rilpivirine. It consists of two active ingredients: cabotegravir, an integrase strand transfer inhibitor (INSTI), and rilpivirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI).
Unlike daily oral pills, Cabenuva is administered as two intramuscular injections (one of cabotegravir and one of rilpivirine) typically once a month or once every two months, after an initial oral lead-in phase. This long-acting formulation aims to improve adherence and reduce the daily burden of medication, offering greater flexibility and privacy for individuals living with HIV.
Reproductive health encompasses a broad range of issues, including fertility, pregnancy, contraception, and sexual health. For individuals on antiretroviral therapy (ART) like Cabenuva, it's vital to consider how the medication might influence these areas. Discussions with a healthcare provider specializing in HIV and reproductive health are paramount to ensure safe and effective management.
The primary concerns regarding Cabenuva and reproductive health typically revolve around:
Current data regarding Cabenuva in some of these areas, particularly pregnancy and breastfeeding, are still evolving, as with many newer medications. Therefore, personalized guidance based on individual circumstances is essential.
Information on the use of Cabenuva during pregnancy is limited, especially for cabotegravir. Most of the data available for antiretroviral drugs during pregnancy come from observational studies and pregnancy registries. While rilpivirine has been more extensively studied in pregnant individuals than cabotegravir, comprehensive data for the combination of Cabenuva are still being gathered.
The general recommendation for individuals with HIV who are pregnant or planning to become pregnant is to discuss their antiretroviral regimen with their healthcare provider. The goal is to select an ART regimen that is effective at suppressing the viral load, well-tolerated by the pregnant individual, and has a known safety profile during pregnancy, minimizing risks to the fetus.
For Cabenuva, the U.S. Department of Health and Human Services (DHHS) Panel on Treatment of HIV-Associated Opportunistic Infections in Adults and Adolescents has provided guidance. They recommend against initiating cabotegravir/rilpivirine (Cabenuva) during pregnancy due to insufficient data on cabotegravir's safety in pregnancy. For individuals who become pregnant while already on Cabenuva and are virologically suppressed, the decision to continue or switch regimens should be made on an individual basis, weighing the benefits of continued viral suppression with the unknown risks to the fetus. Often, switching to an oral regimen with more established safety data during pregnancy may be considered.
Key considerations for Cabenuva use during pregnancy:
For individuals with HIV who are considering pregnancy, proactive planning with a healthcare provider is essential. This includes:
The DHHS Panel recommends against breastfeeding for individuals with HIV in resource-rich settings, regardless of their viral load or ART regimen, due to the persistent, albeit low, risk of postnatal HIV transmission through breast milk. However, in some contexts, or for individuals who make an informed decision to breastfeed, understanding drug transfer into breast milk is important.
Both cabotegravir and rilpivirine are known to be excreted in the milk of lactating rats. While human data are very limited for cabotegravir, rilpivirine has been detected in human breast milk. The potential effects of these drugs on a breastfed infant are unknown. If an individual chooses to breastfeed, close monitoring of the infant for potential adverse effects and regular viral load testing for the infant would be necessary, in consultation with a healthcare provider.
Currently, there is no strong evidence to suggest that Cabenuva directly impacts male or female fertility. Most antiretroviral medications are not known to cause infertility. However, general factors related to chronic HIV infection itself can sometimes affect reproductive health, and it's important to distinguish between drug effects and disease effects.
There are no specific data indicating that Cabenuva significantly affects ovulation, menstrual cycles, or overall female fertility. However, any changes in menstrual patterns or difficulty conceiving should be discussed with a healthcare provider, as other factors may be at play.
Similarly, there is no evidence to suggest that Cabenuva negatively impacts sperm quality, quantity, or male fertility. Men with HIV who are planning to conceive should also consult with their doctor to ensure optimal health and viral suppression.
If fertility concerns arise while on Cabenuva, a thorough medical evaluation is warranted to identify potential causes, which may not be related to the medication itself.
Effective contraception is crucial for individuals who do not wish to become pregnant, especially given the limited data on Cabenuva's use during pregnancy. It's important to be aware of potential drug interactions between Cabenuva and hormonal birth control methods.
Rilpivirine, one of the components of Cabenuva, is known to have potential interactions with certain hormonal contraceptives. Specifically, it can reduce the concentrations of some estrogen-containing hormonal contraceptives. This interaction could potentially make hormonal birth control less effective, increasing the risk of unintended pregnancy.
Cabotegravir, the other component, is not currently known to have significant interactions with hormonal contraceptives. However, when combined as Cabenuva, the interaction profile needs to be considered for the entire regimen.
Given the potential for interaction with hormonal contraceptives, healthcare providers often recommend alternative or additional contraceptive methods for individuals on Cabenuva:
Always inform your healthcare provider about all medications you are taking, including Cabenuva, when discussing contraceptive options. They can help you choose the most effective and safe method based on your individual health profile and preferences.
It is crucial to remember that while Cabenuva is highly effective in treating HIV-1 infection and preventing its progression, it does not protect against other sexually transmitted infections (STIs). This includes common STIs like gonorrhea, chlamydia, syphilis, herpes, and human papillomavirus (HPV).
Therefore, individuals on Cabenuva should continue to practice safe sex, including consistent and correct use of condoms, to prevent the acquisition and transmission of other STIs. Regular STI screening is also recommended, especially for sexually active individuals.
Open and honest communication with your healthcare provider is vital when you are on Cabenuva, especially concerning reproductive health. You should see your doctor or healthcare team if you experience any of the following:
Currently, there is limited data on the safety and efficacy of Cabenuva during human pregnancy. Due to insufficient information, especially for cabotegravir, the U.S. DHHS Panel generally recommends against initiating Cabenuva during pregnancy. If you become pregnant while on Cabenuva, it is crucial to speak with your healthcare provider immediately to discuss the best course of action, which may involve switching to an oral regimen with more established pregnancy safety data.
There is no current evidence to suggest that Cabenuva directly impacts male or female fertility. Most antiretroviral medications are not known to cause infertility. If you have concerns about fertility, discuss them with your healthcare provider, as other factors may be involved.
Yes, but careful consideration is needed. Rilpivirine, a component of Cabenuva, can potentially interact with some hormonal contraceptives, making them less effective. It is important to discuss all your contraceptive options with your healthcare provider. Non-hormonal methods like copper IUDs or barrier methods (condoms) are often recommended. A dual method approach may also be considered.
No, Cabenuva only treats and prevents HIV-1 infection. It does not protect against other STIs such as gonorrhea, chlamydia, syphilis, herpes, or HPV. Consistent and correct use of condoms is essential for preventing other STIs, and regular screening is recommended for sexually active individuals.
Contact your healthcare provider immediately. They will assess your viral load, gestational age, and overall health to determine the safest and most effective treatment plan for you and your baby. This may involve switching to a different antiretroviral regimen with more established safety data in pregnancy.
Cabenuva offers a transformative approach to HIV management with its long-acting injectable formulation, providing convenience and improved quality of life for many. However, like all medications, its use requires careful consideration, particularly concerning reproductive health.
While data on Cabenuva's impact on pregnancy and breastfeeding are still evolving, existing guidelines emphasize the importance of shared decision-making with healthcare providers. For those planning a family or managing their sexual health, open communication with your doctor about pregnancy intentions, contraceptive needs, and any fertility concerns is paramount. By staying informed and working closely with your healthcare team, individuals on Cabenuva can effectively manage their HIV while also making informed choices about their reproductive journey.
Sleeping tablets can help manage insomnia and sleep disorders when used correctly. This guide explains types, benefits, risks, and safe usage tips for better sleep health.
April 11, 2026
Explore the short-term and long-term effects of Adderall on the brain, including its uses, side effects, risks of misuse, and the importance of medical supervision for safe and effective treatment.
April 1, 2026
Curious if Pepto-Bismol can help your stomach after drinking? We explore the potential risks and what the research says about mixing Pepto-Bismol and alcohol, plus safer alternatives for hangover relief.
April 1, 2026